INBX
Inhibrx·NASDAQ
--
--(--)
--
--(--)
INBX fundamentals
During Q4 2025, Inhibrx (INBX) reported revenue of --, a YoY change of 0.00%. Net income was -32.83M, a YoY change of 31.40%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | 17.00K -- | 30.00K -- | 119.00K -- | 1.63M -- | -- -- | 100.00K +233.33% | -- -- | 100.00K -93.88% | -- -- | 1.30M +1200.00% | -- -- | -- -- | -- -- |
Sales and Services Revenue | 17.00K -- | 30.00K -- | 119.00K -- | 1.63M -- | -- -- | 100.00K +233.33% | 0 -100.00% | 100.00K -93.88% | -- -- | 1.30M +1200.00% | 0 -- | 0 -100.00% | -- -- |
Gross Profit | 17.00K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 43.78M -- | 41.37M -- | 45.95M -- | 89.92M -- | 73.83M +68.62% | 161.00M +289.18% | 46.80M +1.85% | 50.03M -44.37% | 42.90M -41.89% | 28.69M -82.18% | 33.81M -27.75% | 30.92M -38.19% | 136.32M -- |
Selling, General and Administrative Expenses | 6.40M -- | 7.26M -- | 7.89M -- | 7.83M -- | 9.97M +55.92% | 93.37M +1185.50% | 7.90M +0.19% | 16.66M +112.73% | 6.02M -39.60% | 6.42M -93.12% | 5.28M -33.24% | 5.57M -66.54% | 23.30M -- |
General and Administrative Expenses | -- -- | 7.26M -- | 7.89M -- | 7.83M -- | 9.97M -- | 93.37M +1185.50% | 7.90M +0.19% | 16.66M +112.73% | 6.02M -39.60% | 6.42M -93.12% | 5.28M -33.24% | 5.57M -66.54% | 23.30M -- |
Research and Development Expenses | 37.39M -- | 34.11M -- | 38.06M -- | 82.09M -- | 63.85M +70.79% | 67.63M +98.30% | 38.89M +2.20% | 33.37M -59.35% | 36.88M -42.25% | 22.27M -67.08% | 28.54M -26.63% | 25.35M -24.03% | 113.03M -- |
Operating Income | -43.77M -- | -41.34M -- | -45.83M -- | -88.29M -- | -73.83M -68.68% | -160.90M -289.22% | -46.80M -2.12% | -49.93M +43.45% | -42.90M +41.89% | -27.39M +82.98% | -33.81M +27.75% | -30.92M +38.06% | -135.03M -- |
Non-Operating Income (Loss) | -5.15M -- | -5.71M -- | -5.96M -- | -5.32M -- | -4.88M +5.15% | 2.02B +35469.85% | 2.93M +149.21% | 2.06M +138.79% | -410.00K +91.61% | -1.26M -100.06% | -1.44M -149.23% | -1.91M -192.63% | -5.03M -- |
Income (Loss) from Affiliates | -- -- | -- -- | -- -- | -1.63M -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Other Non-Operating Income (Loss) | -70.00K -- | -217.00K -- | -135.00K -- | -158.00K -- | -59.00K +15.71% | 2.02B +931681.11% | 41.00K +130.37% | 60.00K +137.97% | -50.00K +15.25% | -246.00K -100.01% | -46.00K -212.20% | -39.00K -165.00% | -381.00K -- |
Net Interest Expense | 5.08M -- | 5.49M -- | 5.83M -- | 3.53M -- | 4.83M -5.00% | 2.62M -52.29% | -2.89M -149.65% | -2.00M -156.79% | 360.00K -92.54% | 1.02M -61.18% | 1.40M +148.34% | 1.87M +193.46% | 4.65M -- |
Interest Expense | 7.56M -- | 7.91M -- | 8.15M -- | 8.22M -- | 8.13M +7.50% | 5.36M -32.18% | 0 -100.00% | 0 -100.00% | 2.69M -66.92% | 3.14M -41.41% | 3.18M -- | 3.19M -- | 12.20M -- |
Interest Income | 2.48M -- | 2.41M -- | 2.32M -- | 4.70M -- | 3.30M +33.06% | 2.74M +13.55% | 2.89M +24.44% | 2.00M -57.35% | 2.33M -29.51% | 2.12M -22.51% | 1.78M -38.35% | 1.31M -34.45% | 7.55M -- |
Pretax Income From Continuing Operations | -48.92M -- | -47.05M -- | -51.79M -- | -93.61M -- | -78.71M -60.91% | 1.86B +4049.27% | -43.86M +15.30% | -47.87M +48.87% | -43.31M +44.97% | -28.65M -101.54% | -35.26M +19.62% | -32.83M +31.40% | -140.05M -- |
Income Tax Expense | -- -- | 5.00K -- | 2.00K -- | -4.00K -- | -- -- | 2.00K -60.00% | 0 -100.00% | -- -- | -- -- | 2.00K -- | 0 -- | -- -- | -- -- |
Current Income Tax | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 2.00K -- | -- -- | -- -- | -- -- | 2.00K -- | -- -- |
Net Income | -48.92M -- | -47.05M -- | -51.79M -- | -93.60M -- | -78.71M -60.91% | 1.86B +4048.85% | -43.86M +15.30% | -47.87M +48.86% | -43.31M +44.97% | -28.65M -101.54% | -35.26M +19.62% | -32.83M +31.40% | -140.06M -- |
Net Income Attributable to Owners of the Company | -48.92M -- | -47.05M -- | -51.79M -- | -93.60M -- | -78.71M -60.91% | 1.86B +4048.85% | -43.86M +15.30% | -47.87M +48.86% | -43.31M +44.97% | -28.65M -101.54% | -35.26M +19.62% | -32.83M +31.40% | -140.06M -- |
Net Income Attributable to Common Stockholders | -48.92M -- | -47.05M -- | -51.79M -- | -93.60M -- | -78.71M -60.91% | 1.86B +4048.85% | -43.86M +15.30% | -47.87M +48.86% | -43.31M +44.97% | -28.65M -101.54% | -35.26M +19.62% | -32.83M +31.40% | -140.06M -- |
Total Comprehensive Income Attributable to Owners of the Company | -- -- | -47.05M -- | -51.79M -- | -93.60M -- | -78.71M -- | 1.86B +4048.85% | -- -- | -- -- | -43.31M +44.97% | -28.65M -101.54% | -- -- | -- -- | -- -- |
Basic EPS | -1.12 -- | -4.31 -- | -4.39 -- | -- -- | -5.77 -415.18% | 127.1 +3048.96% | -2.84 +35.31% | -3.31 -- | -2.8 +51.47% | -1.85 -101.46% | -2.28 +19.72% | -2.25 +32.02% | -9.18 -- |
Basic EPS from Continuing Operations | -- -- | -4.31 -- | -4.39 -- | -- -- | -5.77 -- | 127.1 +3048.96% | -2.84 +35.31% | -- -- | -2.8 +51.47% | -1.85 -101.46% | -2.28 +19.72% | -- -- | -- -- |
Diluted EPS | -1.12 -- | -4.31 -- | -4.39 -- | -- -- | -5.77 -415.18% | 125.48 +3011.37% | -2.84 +35.31% | -- -- | -2.8 +51.47% | -1.85 -101.47% | -2.28 +19.72% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -4.31 -- | -4.39 -- | -- -- | -5.77 -- | 125.48 +3011.37% | -2.84 +35.31% | -- -- | -2.8 +51.47% | -1.85 -101.47% | -2.28 +19.72% | -- -- | -- -- |
You can ask Aime
What does Inhibrx do and what are its main business segments?What were the key takeaways from Inhibrx’s earnings call?What factors drove the changes in Inhibrx's revenue and profit?What were the key takeaways from Inhibrx's earnings call?What is Inhibrx's gross profit margin?Did Inhibrx beat or miss consensus estimates last quarter?What is the market's earnings forecast for Inhibrx next quarter?What is Inhibrx's latest dividend and current dividend yield?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
